Greater ethnic diversity correlates with lower HIV prevalence in Africa: Justification for an alloimmunity vaccine

Christopher Zamani, Jared D. Elzey, James Hildreth

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: After decades of research, AIDS continues to be a major pandemic and to date, adaptive immunity vaccine designs have had little to no success. Data indicate the alloimmune response is a potent mitigator of human immunodeficiency virus (HIV) infection, for which experiments of nature should be demonstrable to justify pursuit of an alloimmune vaccine strategy. We sought to determine if large-scale alloimmune diversity correlates with lower HIV infection rates. Methods: Using published data of African linguistic groups to determine sub-Saharan country ethnicity profiles as a proxy for human leukocyte antigen (HLA) diversity, a correlation analysis was performed against respective sub-Saharan country HIV infection rates. Ethnicity data from 37 sub-Saharan nations in 2003 and from 38 nations in 2005 were used to calculate the Meyers-Macintosh ethnic diversity score for each nation as the independent variable. World Health Organization data on HIV infection rates for the same countries were used as the dependent variable. The main outcome measure was the correlation coefficient of ethnic diversity versus HIV infection rate. Results: A significant negative correlation was shown between ethnic diversity and HIV infection: for 2003 data, -0.4586 (two-tailed P-value of 0.0043); and, for 2005 data, -0.3866 (two-tailed P-value of 0.0165). Conclusion: In conjunction with substantial evidence that alloimmunity confers protection against HIV transmission and recent work identifying specific anti-HIV mechanisms, this analysis strongly justifies an HLA-based alloimmune vaccine strategy against HIV.

Original languageEnglish (US)
Pages (from-to)75-80
Number of pages6
JournalHIV/AIDS - Research and Palliative Care
Volume5
DOIs
StatePublished - Apr 11 2013
Externally publishedYes

Fingerprint

Vaccines
HIV
Virus Diseases
HLA Antigens
Proxy
Adaptive Immunity
Pandemics
Linguistics
Acquired Immunodeficiency Syndrome
Outcome Assessment (Health Care)
Research

Keywords

  • Adaptive immunity
  • AIDS
  • Human leukocyte antigen (HLA)

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology
  • Health Policy
  • Epidemiology
  • Dermatology

Cite this

Greater ethnic diversity correlates with lower HIV prevalence in Africa : Justification for an alloimmunity vaccine. / Zamani, Christopher; Elzey, Jared D.; Hildreth, James.

In: HIV/AIDS - Research and Palliative Care, Vol. 5, 11.04.2013, p. 75-80.

Research output: Contribution to journalArticle

@article{022a1c7904214ff093a444ddece76a20,
title = "Greater ethnic diversity correlates with lower HIV prevalence in Africa: Justification for an alloimmunity vaccine",
abstract = "Purpose: After decades of research, AIDS continues to be a major pandemic and to date, adaptive immunity vaccine designs have had little to no success. Data indicate the alloimmune response is a potent mitigator of human immunodeficiency virus (HIV) infection, for which experiments of nature should be demonstrable to justify pursuit of an alloimmune vaccine strategy. We sought to determine if large-scale alloimmune diversity correlates with lower HIV infection rates. Methods: Using published data of African linguistic groups to determine sub-Saharan country ethnicity profiles as a proxy for human leukocyte antigen (HLA) diversity, a correlation analysis was performed against respective sub-Saharan country HIV infection rates. Ethnicity data from 37 sub-Saharan nations in 2003 and from 38 nations in 2005 were used to calculate the Meyers-Macintosh ethnic diversity score for each nation as the independent variable. World Health Organization data on HIV infection rates for the same countries were used as the dependent variable. The main outcome measure was the correlation coefficient of ethnic diversity versus HIV infection rate. Results: A significant negative correlation was shown between ethnic diversity and HIV infection: for 2003 data, -0.4586 (two-tailed P-value of 0.0043); and, for 2005 data, -0.3866 (two-tailed P-value of 0.0165). Conclusion: In conjunction with substantial evidence that alloimmunity confers protection against HIV transmission and recent work identifying specific anti-HIV mechanisms, this analysis strongly justifies an HLA-based alloimmune vaccine strategy against HIV.",
keywords = "Adaptive immunity, AIDS, Human leukocyte antigen (HLA)",
author = "Christopher Zamani and Elzey, {Jared D.} and James Hildreth",
year = "2013",
month = "4",
day = "11",
doi = "10.2147/HIV.S38922",
language = "English (US)",
volume = "5",
pages = "75--80",
journal = "HIV/AIDS - Research and Palliative Care",
issn = "1179-1373",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Greater ethnic diversity correlates with lower HIV prevalence in Africa

T2 - Justification for an alloimmunity vaccine

AU - Zamani, Christopher

AU - Elzey, Jared D.

AU - Hildreth, James

PY - 2013/4/11

Y1 - 2013/4/11

N2 - Purpose: After decades of research, AIDS continues to be a major pandemic and to date, adaptive immunity vaccine designs have had little to no success. Data indicate the alloimmune response is a potent mitigator of human immunodeficiency virus (HIV) infection, for which experiments of nature should be demonstrable to justify pursuit of an alloimmune vaccine strategy. We sought to determine if large-scale alloimmune diversity correlates with lower HIV infection rates. Methods: Using published data of African linguistic groups to determine sub-Saharan country ethnicity profiles as a proxy for human leukocyte antigen (HLA) diversity, a correlation analysis was performed against respective sub-Saharan country HIV infection rates. Ethnicity data from 37 sub-Saharan nations in 2003 and from 38 nations in 2005 were used to calculate the Meyers-Macintosh ethnic diversity score for each nation as the independent variable. World Health Organization data on HIV infection rates for the same countries were used as the dependent variable. The main outcome measure was the correlation coefficient of ethnic diversity versus HIV infection rate. Results: A significant negative correlation was shown between ethnic diversity and HIV infection: for 2003 data, -0.4586 (two-tailed P-value of 0.0043); and, for 2005 data, -0.3866 (two-tailed P-value of 0.0165). Conclusion: In conjunction with substantial evidence that alloimmunity confers protection against HIV transmission and recent work identifying specific anti-HIV mechanisms, this analysis strongly justifies an HLA-based alloimmune vaccine strategy against HIV.

AB - Purpose: After decades of research, AIDS continues to be a major pandemic and to date, adaptive immunity vaccine designs have had little to no success. Data indicate the alloimmune response is a potent mitigator of human immunodeficiency virus (HIV) infection, for which experiments of nature should be demonstrable to justify pursuit of an alloimmune vaccine strategy. We sought to determine if large-scale alloimmune diversity correlates with lower HIV infection rates. Methods: Using published data of African linguistic groups to determine sub-Saharan country ethnicity profiles as a proxy for human leukocyte antigen (HLA) diversity, a correlation analysis was performed against respective sub-Saharan country HIV infection rates. Ethnicity data from 37 sub-Saharan nations in 2003 and from 38 nations in 2005 were used to calculate the Meyers-Macintosh ethnic diversity score for each nation as the independent variable. World Health Organization data on HIV infection rates for the same countries were used as the dependent variable. The main outcome measure was the correlation coefficient of ethnic diversity versus HIV infection rate. Results: A significant negative correlation was shown between ethnic diversity and HIV infection: for 2003 data, -0.4586 (two-tailed P-value of 0.0043); and, for 2005 data, -0.3866 (two-tailed P-value of 0.0165). Conclusion: In conjunction with substantial evidence that alloimmunity confers protection against HIV transmission and recent work identifying specific anti-HIV mechanisms, this analysis strongly justifies an HLA-based alloimmune vaccine strategy against HIV.

KW - Adaptive immunity

KW - AIDS

KW - Human leukocyte antigen (HLA)

UR - http://www.scopus.com/inward/record.url?scp=84876262306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876262306&partnerID=8YFLogxK

U2 - 10.2147/HIV.S38922

DO - 10.2147/HIV.S38922

M3 - Article

C2 - 23610530

AN - SCOPUS:84876262306

VL - 5

SP - 75

EP - 80

JO - HIV/AIDS - Research and Palliative Care

JF - HIV/AIDS - Research and Palliative Care

SN - 1179-1373

ER -